Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194425 | 0.94 | HTR7 (0.43) | LMNATP53MAPTHTR7HTR1A | |
| SCHEMBL2192165 | 0.94 | HTR7 (0.46) | LMNATP53MAPTHTR7HTR1A | |
| SCHEMBL2195066 | 0.93 | HTR7 (0.45) | LMNATP53MAPTHTR7HTR1A | |
| SCHEMBL2847054 | 0.89 | HTR7 (0.41) | HTR7HTR1ANOTUMADRA1BDRD1 | |
| SCHEMBL1253364 | 0.88 | HTR1A (0.50) | HTR7HTR1AADRA1BDRD1DRD3 | |
| SCHEMBL2848142 | 0.86 | HTR2C (0.43) | HTR7 | |
| SCHEMBL3426445 | 0.85 | HTR7 (0.44) | HTR7HTR1AADRA1BDRD1DRD3 | |
| SCHEMBL2196523 | 0.85 | DRD2 (0.49) | MAPTHTR7HTR1AADRA1BDRD3 | |
| SCHEMBL2197900 | 0.83 | HTR7 (0.46) | HTR7HTR1AADRA1BDRD1DRD3 | |
| SCHEMBL2191705 | 0.83 | HTR7 (0.44) | HTR7HTR1ANOTUMADRA1BDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-8598180-B2 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1715921-B1 | Tetrahydroindolone derivatives for treatment of neurological conditions | ABRAXIS BIOSCIENCE INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | ABRAXIS BIOSCIENCE, INC. | 2010-12-02 | — | — | US | disclosed |
| US-7795266-B2 | Tetrahydroindolone derivatives for treament of neurological conditions | ABRAXIS BIOSCIENCE, INC. | 2010-09-14 | — | — | US | disclosed |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | ABRAXIS BIOSCIENCE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208030-A1 | Tetrahydroindolone Derivatives for Treament of Neurological Conditions | TPH2, TPH1, GRIK5 | LMNA 1521/4885TP53 4408/4885MAPT 23/4885 |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | HTR5A, HTR2C, HTR3B | LMNA 4576/4885TP53 4868/4885MAPT 2521/4885 |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | LMNA 4193/4885TP53 1026/4885MAPT 3987/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | LMNA 4193/4885TP53 1026/4885MAPT 3987/4885 |
| US-20100305141-A1 | TETRAHYDROINDOLONE DERIVATIVES FOR TREATMENT OF NEUROLOGICAL CONDITIONS | NLN, CYP11B2, GRIN2C | LMNA 1832/4885TP53 4401/4885MAPT 80/4885 |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | LMNA 4193/4885TP53 1026/4885MAPT 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.